🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are escalating around the world, with figures suggesting in excess of 82 million new cases each year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune step in the context of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This approval represents a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

As per findings detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of cases of the STI. This establishes an similar efficacy with the typical regimen, which combines an injection and a pill. The research enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to license and sell the drug in numerous developing nations.

Clinicians on the front lines have voiced positive views. The availability of a easy-to-administer therapy of this kind is described as a "revolutionary step" for gonorrhoea control. This is considered crucial to reduce the burden of the infection for individuals and to halt the transmission of untreatable gonorrhoea around the world.